News >

Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline

Chelsea LoCascio
Published: Monday, Oct 30, 2017

Howard A. “Skip” Burris, MD

Howard A. “Skip” Burris, MD
Ongoing clinical trials are exploring novel approaches in triple-negative breast cancer (TNBC), such as PARP inhibition and immunotherapy.

Early promise has already been observed, as phase Ib/II findings found that a combination of eribulin (Halaven) and pembrolizumab (Keytruda) was associated with an objective response rate (ORR) of 41.2% for untreated patients with metastatic TNBC.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication